High-throughput measurement of 41Ca by accelerator mass spectrometry to quantitate small changes in individual human bone turnover rates

Darren J. Hillegonds, Robert Fitzgerald, David Herold, Yumei Lin, John S. Vogel

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Biochemical markers of bone turnover suffer from large analytical and natural fluctuations (20-30%), making small differences in bone resorption impossible to resolve. This limits the clinical utility of such markers for individuals with the skeletal complications associated with many disease states (e.g., metastatic cancer, renal failure, osteoporosis). We are developing the capability to measure small changes (5-10%) in bone turnover rate in vivo by tagging the living skeleton with 41Ca. Among the stable and radioactive calcium isotopes, only 41Ca is useful for direct quantitation of bone turnover because it is extremely rare in nature and radiologically benign (105 years half-life, pure electron capture decay). The ratio of this tracer to total calcium remains quantifiable in body fluids and excreta via accelerator mass spectrometry (AMS) for many years following a single physiological-sized oral or intravenous dose. The highly automated AMS instrumentation and streamlined sample preparation allows a single operator to prepare or run more than 100 samples per day-significantly more than other 41Ca programs worldwide. We intend to exploit these measurements for earlier diagnosis of pathological processes and interactive intervention with therapeutic agents, allowing modulation of these agents to obtain the best individual result for a patient.

Original languageEnglish (US)
Pages (from-to)99-102
Number of pages4
JournalJALA - Journal of the Association for Laboratory Automation
Volume9
Issue number3
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Bone Remodeling
Particle accelerators
Mass spectrometry
Mass Spectrometry
Bone
Throughput
Calcium Isotopes
Calcium
Body Fluids
Pathologic Processes
Bone Resorption
Skeleton
Radioisotopes
Osteoporosis
Renal Insufficiency
Half-Life
Early Diagnosis
Body fluids
Biomarkers
Electrons

Keywords

  • Accelerator mass spectrometry
  • Calcium homeostasis
  • Metastatic bone disease

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

High-throughput measurement of 41Ca by accelerator mass spectrometry to quantitate small changes in individual human bone turnover rates. / Hillegonds, Darren J.; Fitzgerald, Robert; Herold, David; Lin, Yumei; Vogel, John S.

In: JALA - Journal of the Association for Laboratory Automation, Vol. 9, No. 3, 06.2004, p. 99-102.

Research output: Contribution to journalArticle

Hillegonds, Darren J. ; Fitzgerald, Robert ; Herold, David ; Lin, Yumei ; Vogel, John S. / High-throughput measurement of 41Ca by accelerator mass spectrometry to quantitate small changes in individual human bone turnover rates. In: JALA - Journal of the Association for Laboratory Automation. 2004 ; Vol. 9, No. 3. pp. 99-102.
@article{57619ed73bea41e1867bb6e4ebb38b79,
title = "High-throughput measurement of 41Ca by accelerator mass spectrometry to quantitate small changes in individual human bone turnover rates",
abstract = "Biochemical markers of bone turnover suffer from large analytical and natural fluctuations (20-30{\%}), making small differences in bone resorption impossible to resolve. This limits the clinical utility of such markers for individuals with the skeletal complications associated with many disease states (e.g., metastatic cancer, renal failure, osteoporosis). We are developing the capability to measure small changes (5-10{\%}) in bone turnover rate in vivo by tagging the living skeleton with 41Ca. Among the stable and radioactive calcium isotopes, only 41Ca is useful for direct quantitation of bone turnover because it is extremely rare in nature and radiologically benign (105 years half-life, pure electron capture decay). The ratio of this tracer to total calcium remains quantifiable in body fluids and excreta via accelerator mass spectrometry (AMS) for many years following a single physiological-sized oral or intravenous dose. The highly automated AMS instrumentation and streamlined sample preparation allows a single operator to prepare or run more than 100 samples per day-significantly more than other 41Ca programs worldwide. We intend to exploit these measurements for earlier diagnosis of pathological processes and interactive intervention with therapeutic agents, allowing modulation of these agents to obtain the best individual result for a patient.",
keywords = "Accelerator mass spectrometry, Calcium homeostasis, Metastatic bone disease",
author = "Hillegonds, {Darren J.} and Robert Fitzgerald and David Herold and Yumei Lin and Vogel, {John S.}",
year = "2004",
month = "6",
doi = "10.1016/j.jala.2004.04.015",
language = "English (US)",
volume = "9",
pages = "99--102",
journal = "Journal of laboratory automation",
issn = "2211-0682",
publisher = "Association for Laboratory Automation",
number = "3",

}

TY - JOUR

T1 - High-throughput measurement of 41Ca by accelerator mass spectrometry to quantitate small changes in individual human bone turnover rates

AU - Hillegonds, Darren J.

AU - Fitzgerald, Robert

AU - Herold, David

AU - Lin, Yumei

AU - Vogel, John S.

PY - 2004/6

Y1 - 2004/6

N2 - Biochemical markers of bone turnover suffer from large analytical and natural fluctuations (20-30%), making small differences in bone resorption impossible to resolve. This limits the clinical utility of such markers for individuals with the skeletal complications associated with many disease states (e.g., metastatic cancer, renal failure, osteoporosis). We are developing the capability to measure small changes (5-10%) in bone turnover rate in vivo by tagging the living skeleton with 41Ca. Among the stable and radioactive calcium isotopes, only 41Ca is useful for direct quantitation of bone turnover because it is extremely rare in nature and radiologically benign (105 years half-life, pure electron capture decay). The ratio of this tracer to total calcium remains quantifiable in body fluids and excreta via accelerator mass spectrometry (AMS) for many years following a single physiological-sized oral or intravenous dose. The highly automated AMS instrumentation and streamlined sample preparation allows a single operator to prepare or run more than 100 samples per day-significantly more than other 41Ca programs worldwide. We intend to exploit these measurements for earlier diagnosis of pathological processes and interactive intervention with therapeutic agents, allowing modulation of these agents to obtain the best individual result for a patient.

AB - Biochemical markers of bone turnover suffer from large analytical and natural fluctuations (20-30%), making small differences in bone resorption impossible to resolve. This limits the clinical utility of such markers for individuals with the skeletal complications associated with many disease states (e.g., metastatic cancer, renal failure, osteoporosis). We are developing the capability to measure small changes (5-10%) in bone turnover rate in vivo by tagging the living skeleton with 41Ca. Among the stable and radioactive calcium isotopes, only 41Ca is useful for direct quantitation of bone turnover because it is extremely rare in nature and radiologically benign (105 years half-life, pure electron capture decay). The ratio of this tracer to total calcium remains quantifiable in body fluids and excreta via accelerator mass spectrometry (AMS) for many years following a single physiological-sized oral or intravenous dose. The highly automated AMS instrumentation and streamlined sample preparation allows a single operator to prepare or run more than 100 samples per day-significantly more than other 41Ca programs worldwide. We intend to exploit these measurements for earlier diagnosis of pathological processes and interactive intervention with therapeutic agents, allowing modulation of these agents to obtain the best individual result for a patient.

KW - Accelerator mass spectrometry

KW - Calcium homeostasis

KW - Metastatic bone disease

UR - http://www.scopus.com/inward/record.url?scp=3042643905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042643905&partnerID=8YFLogxK

U2 - 10.1016/j.jala.2004.04.015

DO - 10.1016/j.jala.2004.04.015

M3 - Article

AN - SCOPUS:3042643905

VL - 9

SP - 99

EP - 102

JO - Journal of laboratory automation

JF - Journal of laboratory automation

SN - 2211-0682

IS - 3

ER -